La mort subite: de l' épidémiologie à la prévention [Sudden cardiac death: epidemiology and modern therapy].

Sudden Cardiac Death (SCD) has become an important public health challenge in the Western World. In Switzerland near 10,000 people suffer each year from SCD. The survival from SCD to hospital discharge is discouraging (near 5%). Large majority of events occur unexpectedly in the out-of-hospital environment and are not predicted with great accuracy by risk profiling. Because the majority of SCD occur by the mechanism of ventricular fibrillation, community-based defibrillation strategies have emerged as one approach to SCD problem. Newer strategies of defibrillation designed to respond faster to out-of-hospital cardiac arrest, including public access defibrillation, as well as aggressive primary and secondary prevention of coronary artery disease appears as the best approach for successful management of SCD.

Ombres et lumières de l'accès public a la défibrillation [Public access defibrillation]

La stratégie d'accès public à la défibrillation (APD) comprend l'installation de défibrillateurs automatiques externes (DAE) dans les lieux publics et l'entraînement de sauveteurs non professionnels à la réanimation cardio pulmonaire et à la défibrillation (RCP-D). Cette approche est recommandée pour le traitement des arrêts cardiaques (ACR) dans les lieux publics. Beaucoup d'études d'observation, mais peu d'études randomisées s'intéressant à cette approche ont été publiées. Cet article résume les différentes approches proposées dans le cadre d'APD. A notre avis, l'installation de DAE dans des lieux publics ou le choix d'une stratégie alternative doivent être précédés d'une étude de la démographie locale des ACR et de l'entraînement du plus grand nombre possible de laïcs à la reconnaissance des signes précurseurs d'ACR et au massage cardiaque externe. Placement of automated external defibrillators (AED) in public facilities and training of the lay persons in basic life support-defibrillation (BLS-D) was recommended by the American Heart Association for the treatment of out-of-hospital cardiac arrest (OHCA). Immediate use of AED result in increase of survival to hospital discharge. Many observation and much less randomized trials describe clinical efficacy of this approach. However, "negative" trials have also been published and some recent data suggest that public access defibrillation (PAD) will have a minimal impact on population survival. In this article various PAD strategies were briefly reviewed. In our opinion installation of AED in public places should be based on the long-term study of local OHCA demography and preceded by widespread BLS training of lay population.

Une insuffisance cardiaque traitée par glucocorticoïdes [A heart insufficiency treated by glucocorticoids]

Arrhythmogenic right ventricular dysplasia was diagnosed in 2000 in this 44-year-old male patient with a history of syncope. An internal defibrillator was implanted. Six years later the patient was readmitted with severe heart failure, and cardiac sarcoidosis was diagnosed by myocardial biopsy. Response to a course of glucorticoids was favourable. We herein review diagnostic strategies and therapeutic options in this rare disorder.

Analyses of a novel SCN5A mutation (C1850S): conduction vs. repolarization disorder hypotheses in the Brugada syndrome.

AIMS: Brugada syndrome (BrS) is characterized by arrhythmias leading to sudden cardiac death. BrS is caused, in part, by mutations in the SCN5A gene, which encodes the sodium channel alpha-subunit Na(v)1.5. Here, we aimed to characterize the biophysical properties and consequences of a novel BrS SCN5A mutation. METHODS AND RESULTS: SCN5A was screened for mutations in a male patient with type-1 BrS pattern ECG. Wild-type (WT) and mutant Na(v)1.5 channels were expressed in HEK293 cells. Sodium currents (I(Na)) were analysed using the whole-cell patch-clamp technique at 37 degrees C. The electrophysiological effects of the mutation were simulated using the Luo-Rudy model, into which the transient outward current (I(to)) was incorporated. A new mutation (C1850S) was identified in the Na(v)1.5 C-terminal domain. In HEK293 cells, mutant I(Na) density was decreased by 62% at -20 mV. Inactivation of mutant I(Na) was accelerated in a voltage-dependent manner and the steady-state inactivation curve was shifted by 11.6 mV towards negative potentials. No change was observed regarding activation characteristics. Altogether, these biophysical alterations decreased the availability of I(Na). In the simulations, the I(to) density necessary to precipitate repolarization differed minimally between the two genotypes. In contrast, the mutation greatly affected conduction across a structural heterogeneity and precipitated conduction block. CONCLUSION: Our data confirm that mutations of the C-terminal domain of Na(v)1.5 alter the inactivation of the channel and support the notion that conduction alterations may play a significant role in the pathogenesis of BrS.

Assessment of the teaching-learning process in students of the health area: cardiopulmonary resuscitation maneuvers

OBJECTIVETo evaluate the skills and knowledge of undergraduate students in the health area on cardiopulmonary resuscitation maneuvers with the use of an automatic external defibrillator.METHODThe evaluation was performed in three different stages of the teaching-learning process. A theoretical and practical course was taught and the theoretical classes included demonstration. The evaluation was performed in three different stages of the teaching-learning process. Two instruments were applied to evaluate the skills (30-items checklist) and knowledge (40-questions written test). The sample comprised 84 students.RESULTSAfter the theoretical and practical course, an increase was observed in the number of correct answers in the 30-items checklist and 40-questions written test.CONCLUSIONAfter the theoretical class (including demonstration), only one of the 30-items checklist for skills achieved an index ≥ 90% of correct answers. On the other hand, an index of correct answers greater than 90% was achieved in 26 (86.7%) of the 30 items after a practical training simulation, evidencing the importance of this training in the defibrillation procedure.

Cardiac re-synchronization therapy in a patient with isolated ventricular non-compaction: a case report.

Isolated ventricular non-compaction (IVNC) is a rare, congenital, unclassified cardiomyopathy characterized by prominent trabecular meshwork and deep recesses. Major clinical manifestations of IVNC are heart failure, atrial and ventricular arrhythmias, and thrombo-embolic events. We describe a case of a 69-year-old woman in whom the diagnosis of IVNC was discovered late, whereas former echocardiographic examinations were considered normal. She was known for systolic left ventricular dysfunction for 3 years and then became symptomatic (NYHA III). In the past, she suffered from multiple episodes of deep vein thrombosis and pulmonary embolism. Electrocardiogram revealed a wide QRS complex, and transthoracic echocardiography showed typical apical thickening of the left and right ventricular myocardial wall with two distinct layers. The ratio of non-compacted to compacted myocardium was >2:1. Cardiac MRI confirmed the echocardiographic images. Cerebral MRI revealed multiple ischaemic sequellae. In view of the persistent refractory, heart failure in medical treatment of patients with classical criteria for cardiac re-synchronization therapy, as well as the ventricular arrhythmias, a biventricular automatic intracardiac defibrillator (biventricular ICD) was implanted. The 2-year follow-up period was characterized by improvement of NYHA functional class from III to I and increasing in left ventricular function. We hereby present a case of IVNC with favourable outcome after biventricular ICD implantation. Cardiac re-synchronization therapy could be considered in the management of this pathology.

Brugada syndrome unmasked by accidental inhalation of gasoline vapors.

Loss-of-function mutations in the gene SCN5A can cause Brugada syndrome (BrS), which is an inherited form of idiopathic ventricular fibrillation. We report the case of a 46-year-old patient, with no previous medical history, who had ventricular fibrillation after accidental inhalation of gasoline vapors. His electrocardiogram (ECG) showed a typical type-1 BrS pattern that persisted after the acute event. Genetic investigations allowed the identification of a novel SCN5A mutation leading to a frame-shift and early termination of the channel protein. Biochemical and cellular electrophysiology experiments confirmed the loss-of-function of the mutant allele. The patient was implanted with a cardioverter/defibrillator.

Défibrillateur automatique implantable (DAI): principes de base et indications cliniques actuelles [Implantable cardiac defibrillator (ICD): basics and present clinical guidelines].

An implantable cardiac defibrillator (ICD) is a cardiac implantable electronic device that is capable of identifying and treating ventricular arrhythmias. Consideration about the type of ICD to select for a given patient include whether the patient has bradycardia requiring pacing support, has associated atrial tachyarrhythmias, or would benefit from cardiac resynchronization therapy. The ICD functions by continuously monitoring the patient's cardiac rate and delivering therapies (anti-tachycardia pacing, shocks) when the rate exceeds the programmed rate "cutoff". Secondary prevention trials have demonstrated that ICDs reduce the incidence of arrhythmic death and total mortality in patients presenting with a cardiac arrest. ICDs are also indicated for primary prevention of sudden cardiac death in specific high-risk subgroups of patients.

Cardiologie [Cardiology update in 2014].

Important clinical trials and therapeutic advances in the field of cardiology have been presented in 2014. New evidences on the management of acute myocardial infarction and the duration of dual antiplatelet therapy after coronary stent implantation have been published. A new class of therapeutic agents seems to offer promising perspectives for patients with heart failure and reduced ejection fraction. The new generation of subcutaneous or MRI-compatible implantable defibrillators is a major technological breakthrough. Finally, the European Society of Cardiology published new recommendations for the management of patients with cardiovascular diseases. This selective review of the literature summarizes the most important studies in the field of interventional cardiology, rhythmology, heart failure and cardiac imaging.

Évaluation d’une intervention infirmière basée sur une approche caring et cognitive comportementale sur l’acceptation d’un défibrillateur cardiaque implantable

Le taux de mortalité chez les patients à risque d’arythmies cardiaques menaçantes à la vie a été considérablement réduit grâce au défibrillateur cardiaque implantable (DCI). Toutefois, des préoccupations uniques face au DCI, y compris les chocs que l’appareil peut déclencher, sont susceptibles de provoquer des symptômes d'anxiété et une limitation perçue des activités chez les porteurs de DCI. Ces réactions émotives et modifications de comportement peuvent affecter l’acceptation du patient envers le DCI. Cette étude pilote randomisée avec groupe contrôle (n=15 /groupe) visait à examiner la faisabilité et l'acceptabilité d'une intervention infirmière individualisée de même que ses effets préliminaires sur l’anxiété, le fonctionnement dans les activités de la vie quotidienne et l’acceptation du DCI auprès de nouveaux porteurs de DCI. L'intervention infirmière, basée sur la théorie du Human Caring et teintée d’une approche cognitive comportementale, ciblait les préoccupations individuelles face au DCI. À partir des préoccupations identifiées, l’infirmière intervenait en mettant l'accent sur les croyances contraignantes du patient, qui pouvaient mener à de l’anxiété et des comportements d'évitement. Après randomisation, les patients du groupe intervention (GI) ont participé à un premier entretien en face-à-face avant le congé hospitalier. Subséquemment, deux entretiens se sont faits par téléphone, à environ 7 et 14 jours suite au congé hospitalier. Les résultats soutiennent la faisabilité et l’acceptabilité du devis de l’étude et de l’intervention évaluée. De plus, ils soulignent le potentiel de l’intervention à diminuer les sentiments anxieux chez les participants du GI. Les résultats de cette étude pilote offrent des pistes de recherches futures et permettront de guider la pratique clinique.

Manejo de cardiomiopatia chagasica : revisión sistemática (1996-2010)

La cardiomiopatía chagásica es la más importante y severa manifestación de la enfermedad crónica, los pacientes pueden cursar con falla cardiaca, arritmias, bloqueos cardiacos, tromboembolismo y muerte súbita. El diagnóstico es tardío, debido a que se confunden con cardiopatías de otra etiología y el manejo se realiza con base en guías y protocolos dirigidos hacia el tratamiento de falla cardiaca de origen no chagásico. Métodos: Se realizó una revisión sistemática y tuvo como objetivo responder a las siguientes Preguntas clínicas: PREGUNTA 1. ¿El manejo actual para la cardiomiopatía chagásica (betabloqueadores, IECA, ARA II, Diuréticos, Inhibidores de la fosfodiesterasa, Estatinas, antiagragantes plaquetarios) que es extrapolado del manejo de falla cardiaca de origen no chagásico tiene impacto en la calidad de vida, sobrevida, seguridad, estancia hospitalaria y disminución del número de hospitalizaciones, mejoría de síntomas, de los pacientes adultos con cardiopatía chagásica?. PREGUNTA 2. ¿En pacientes con cardiomiopatía chagásica el uso de fármacos tripanocidas mejora la sobrevida, calidad de vida, estancia hospitalaria, disminución del número de hospitalizaciones, y resolución de síntomas? PREGUNTA 3. ¿En pacientes con cardiomiopatía chagásica el uso de cardiodesfibriladores mejora la sobrevida, calidad de vida, estancia hospitalaria, disminución del número de hospitalizaciones, y resolución de síntomas? PREGUNTA 4. ¿En pacientes con cardiomiopatía chagásica el uso de marcapasos mejora la sobrevida, calidad de vida, estancia hospitalaria, disminución del número de hospitalizaciones, y resolución de síntomas? PREGUNTA 5. ¿En pacientes con cardiomiopatía chagásica el uso de trasplante de corazón mejora la sobrevida, calidad de vida, estancia hospitalaria, disminución del número de hospitalizaciones, y resolución de síntomas? Se realizaron búsquedas en: MEDLINE, Colaboración Cochrane, Trip database, y otras importantes bases de datos desde 1996 hasta 2010, limitando la búsqueda. Los estudios se seleccionaron de acuerdo a criterios de pertinencia PICO y se evaluó la calidad, usando la metodología recomendada en Scottish Intercollegiate Guidelines Network. Resultados: Se encontraron 21 estudios, que incluyen revisiones sistemáticas, ensayos clínicos controlados y aleatorizados, ensayos clínicos, cohortes y, casos y controles. Estos estudios cumplieron con los criterios de inclusión. Discusión: En esta revisión sistemática se presenta un consolidado de la evidencia disponible acerca de la eficacia de las siguientes intervenciones: Betabloqueadores, IECAS, PDE, Digoxina, nitroderivados, cardiodesfibriladores, marcapasos y trasplante de corazón, en pacientes con cardiopatía chagásica; los estudios encontrados en su mayoría son de baja evidencia.

Incidencia de fibrilación auricular en pacientes con dispositivos de estimulación cardiaca con cardiopatía chagásica y no chagásica

La posible asociación entre el desarrollo de fibrilación auricular (FA) con la presencia de cardiopatía chagásica en una población portadora de dispositivos cardiacos de estimulación no está descrita. Se presenta un estudio de tipo cohorte retrospectivo realizado en la FCI que recopila las principales características clínicas de una población de pacientes con cardiopatía de variada etiología y portadores de dispositivos cardiacos buscando evaluar la incidencia de FA en presencia de cardiomiopatía de origen chagásico y no chagásico. A la fecha no se cuenta con una base de datos institucional ni regional que contenga las variables analizadas. Durante los 5 meses que duró la construcción de la base de datos se incluyeron 99 sujetos de investigación. Se implantaron 42 marcapasos bicamerales, 39 cardiodesfibriladores bicamerales, 6 dispositivos correspondientes cardiodesfibrilador con función de resincronización cardiaca, 2 resincronizadores cardiacos sin función de cardiodesfibrilador y 7 cardiodesfibriladores unicamerales. De los 99 sujetos recolectados se presentaron 8 desenlaces (FA de novo) y de esos solamente 1 pertenece al grupo de pacientes con cardiomiopatía chagásica. Este número reducido de desenlaces no permitió desarrollar un modelo de regresión de Cox y ni otros tipos de análisis estadísticos planteados en el protocolo inicial debido al bajo número de casos y pobre poder estadístico. Esta dificultad es inherente a la naturaleza del problema a estudiar y al corto tiempo de seguimiento. Por lo anterior no se puede establecer si existe una relación entre la presencia de serología positiva para infección por T. Cruzi y la presencia de FA de novo.

Asociación de la concentración de material particulado en Bogotá con infarto agudo de miocardio

Introducción: la contaminación atmosférica no solo tiene efectos sobre el sistema respiratorio sino también sobre el cardiovascular. El objetivo de este estudio es generar evidencia que permita establecer una asociación entre el infarto agudo del miocardio y la concentración de PM10 en el ambiente como un estudio preliminar para un grupo de pacientes en Bogotá. Metodología: la asociación entre la concentración del material particulado (en este caso PM10 medido en la estación más cercana del lugar reportado por el paciente) y el infarto agudo del miocardio se estableció utilizando el diseño case crossover. Se utilizó información de las historias clínicas de los pacientes con infarto agudo del miocardio que ingresaron al Servicio de Urgencias de la FSFB, y las concentraciones de PM10 medido en la estación más cercana al lugar de inicio de los síntomas de síndrome coronario agudo, reportado por el paciente. Resultados: se encontró que la asociación entre la concentración de PM10 y el diagnóstico de infarto agudo del miocardio es estadísticamente significativa teniendo en cuenta tres momentos de control: 2 horas antes del evento, 24 horas antes del evento y 48 horas antes del evento. Discusión: este estudio sugiere que las altas concentraciones de material particulado en el ambiente son un factor de riesgo para el desarrollo de infarto agudo del miocardio especialmente en personas con enfermedad coronaria subyacente. Con esta investigación se demuestra la importancia de generar acciones que disminuyan la contaminación de la ciudad y de esta forma proteger la salud de las personas.

Omega-3 fatty acids, cardiovascular disease and stability of atherosclerotic plaques

Long-chain n-3 polyunsaturated fatty acids are found in oily fish and in fish oils and similar preparations. Substantial evidence from epidemiological and case-control studies indicates that consumption of fish, oily fish and long-chain n-3 fatty acids reduces risk of cardiovascular mortality. Secondary prevention studies using long-chain n-3 fatty acids in patients post-myocardial infarction have shown a reduction in total and cardiovascular mortality with an especially potent effect on sudden death. Long-chain n-3 fatty acids have been shown to beneficially modify a range of cardiovascular risk factors, which may result in primary cardiovascular prevention. However, reduced non-fatal and fatal events and a reduction in sudden death probably involve other mechanisms. Reduced thrombosis following long-chain n-3 fatty acids may play a role. A decrease in arrhythmias is a favoured mechanism of action of long-chain n-3 fatty acids and is supported by cell culture and animal studies. However human trials using implantable cardiac defibrillators have produced inconsistent findings and a recent meta-analysis does not support this mechanism of action. An alternative mechanism of action may be stabilisation of atherosclerotic plaques by long-chain n-3 fatty acids. This is suggested by one published human study which showed that incorporation of long-chain n-3 fatty acids into plaques collected at carotid endarterectomy resulted in fewer macrophages in the plaque and a morphology indicative of increased stability. These findings are supported from observations in an animal model and suggest that the primary effect of long-chain n-3 fatty acids might be on macrophages within the plaque.

Metodologia de avaliação metrológica da medição de energia para analisadores de desfibriladores e cardioversores

Neste artigo descreve-se uma pesquisa na qual se desenvolveu um analisador de desfibriladores e cardioversores e se executou sua avaliação metrológica, sendo apresentados os resultados obtidos. A avaliação das incertezas de medição do analisador foi realizada de acordo com as determinações da versão brasileira do EA-4/02 - Expressão da Incerteza de Medição de Calibração publicado pelo INMETRO. Os resultados obtidos mostraram-se adequados às exigências de exatidão determinadas pelas normas ANSI/AAMI DF2 (American..., 1996) e ANSI/AAMI DF80 (American..., 2003), tendo apresentado uma incerteza expandida relativa para as medições de energia igual a 1,0% no pior caso. Nesta pesquisa foi também realizada uma análise da incerteza definicional do processo de calibração utilizado e avaliou-se a capacidade do processo. Para os cálculos da capacidade do processo, foi determinado um erro máximo para as medições de energia igual a 5% ou 1,0 J, o que for maior. Este erro máximo é igual a 1/3 do erro máximo admissível para a energia entregue pelos desfibriladores, em outras palavras, é igual ao erro máximo admissível para um instrumento de medição pela Norma ANSI/AAMI DF2 (American..., 1996). Os resultados obtidos para a capacidade do procedimento de calibração mostraram-se adequados para as especificações de um analisador de desfibriladores e cardioversores, tendo obtido como resultado, no pior caso, um índice de capacidade Cm igual a 2,87, que é bem superior, portanto, a 1,0, sendo este o limite mínimo para que o procedimento seja considerado capaz de calibrar a medição de energia sem atribuir uma incerteza definicional demasiadamente grande.